Women’s healthcare startup SheMed has raised $50 million in Series A funding, bringing its valuation to $1 billion and earning unicorn status less than a year after its founding in April 2024. The UK-based company has rapidly expanded its GLP-1 weight management program, serving over 60,000 members seeking more precise and compassionate care. According to Co-Founder and CEO Olivia Ferro, “Achieving unicorn status validates the scale of the unmet needs for world-class GLP-1 care. Having been a GLP-1 patient myself, I know how transformative the right diagnosis and treatment can be. We built SheMed to give women the personalised support I struggled to find: care that listens, understands, and empowers.”
The new funding will be directed toward expanding operations, strengthening clinical infrastructure, and supporting female-focused research, including the first-ever GLP-1 clinical study for women. Co-Founder and President Chloe Ferro said, “The demand for SheMed’s services has been extraordinary. Women are seeking care that recognizes their individuality, their biology, and their experiences.”
